Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,558
  • Shares Outstanding, K 33,192
  • Annual Sales, $ 0 K
  • Annual Income, $ -79,980 K
  • EBIT $ -79 M
  • EBITDA $ -79 M
  • 60-Month Beta 0.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.17
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.51
  • Most Recent Earnings $-0.58 on 05/12/25
  • Next Earnings Date 08/06/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 374.72% ( +117.63%)
  • Historical Volatility 118.77%
  • IV Percentile 72%
  • IV Rank 41.03%
  • IV High 897.86% on 04/16/25
  • IV Low 10.76% on 08/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 73
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 3,595
  • Open Int (30-Day) 3,624

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.46
  • Prior Year -0.59
  • Growth Rate Est. (year over year) +57.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3606 +95.84%
on 05/13/25
0.9000 -21.53%
on 06/06/25
+0.3079 (+77.30%)
since 05/12/25
3-Month
0.2430 +190.62%
on 04/09/25
0.9000 -21.53%
on 06/06/25
+0.4362 (+161.56%)
since 03/12/25
52-Week
0.2404 +193.76%
on 03/03/25
4.4700 -84.20%
on 07/11/24
-2.3238 (-76.69%)
since 06/12/24

Most Recent Stories

More News
Relmada Therapeutics Announces Discontinuation of Reliance II and Relight Phase 3 Studies, Explores Strategic Alternatives

Relmada Therapeutics discontinues Phase 3 studies and explores strategic alternatives to enhance shareholder value.Quiver AI SummaryRelmada Therapeutics, Inc., a biotechnology company focused on central...

RLMD : 0.7062 (-8.29%)
Relmada Therapeutics Initiates Phase 1 Study of REL-P11, a Low-Dose Psilocybin Formulation for Metabolic Disease

Relmada initiates Phase 1 study for REL-P11, a psilocybin formulation for metabolic disorders, with Phase 2a planned for 2025.Quiver AI SummaryRelmada Therapeutics has announced the initiation of dosing...

RLMD : 0.7062 (-8.29%)
2 Breakout Biotech Stocks With CEO Insider Buying

These two breakout stocks are on a stellar run higher on the charts, but should investors follow executives into the shares?

RLMD : 0.7062 (-8.29%)
DYN : 14.46 (-0.75%)
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 0.7062 (-8.29%)
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 0.7062 (-8.29%)
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 0.7062 (-8.29%)
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 0.7062 (-8.29%)
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 0.7062 (-8.29%)
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 0.7062 (-8.29%)
Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 0.7062 (-8.29%)

Business Summary

Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an...

See More

Key Turning Points

3rd Resistance Point 0.8633
2nd Resistance Point 0.8367
1st Resistance Point 0.8033
Last Price 0.7062
1st Support Level 0.7433
2nd Support Level 0.7167
3rd Support Level 0.6833

See More

52-Week High 4.4700
Fibonacci 61.8% 2.8543
Fibonacci 50% 2.3552
Fibonacci 38.2% 1.8561
Last Price 0.7062
52-Week Low 0.2404

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar